United Therapeutics Co. (NASDAQ:UTHR) CEO Sells $951,192.00 in Stock

United Therapeutics Co. (NASDAQ:UTHR - Get Free Report) CEO Martine A. Rothblatt sold 3,600 shares of the firm's stock in a transaction on Thursday, May 9th. The stock was sold at an average price of $264.22, for a total value of $951,192.00. Following the completion of the transaction, the chief executive officer now directly owns 130 shares of the company's stock, valued at $34,348.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

United Therapeutics Stock Down 0.7 %

Shares of UTHR stock traded down $1.78 on Friday, hitting $264.27. 391,702 shares of the stock were exchanged, compared to its average volume of 464,290. The firm has a market capitalization of $11.72 billion, a P/E ratio of 12.58 and a beta of 0.54. United Therapeutics Co. has a fifty-two week low of $204.44 and a fifty-two week high of $269.81. The business has a 50-day moving average of $239.87 and a 200 day moving average of $230.35. The company has a current ratio of 3.77, a quick ratio of 3.64 and a debt-to-equity ratio of 0.04.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.63 by $0.54. The business had revenue of $677.70 million for the quarter, compared to the consensus estimate of $620.31 million. United Therapeutics had a return on equity of 18.72% and a net margin of 42.05%. United Therapeutics's quarterly revenue was up 33.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $4.86 earnings per share. Equities analysts anticipate that United Therapeutics Co. will post 23.88 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on UTHR shares. Wedbush reissued an "outperform" rating and issued a $308.00 price target on shares of United Therapeutics in a research report on Thursday, February 22nd. StockNews.com cut shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Thursday, April 11th. The Goldman Sachs Group lifted their price objective on United Therapeutics from $218.00 to $240.00 and gave the stock a "neutral" rating in a research report on Friday, May 3rd. Leerink Partnrs reiterated an "outperform" rating on shares of United Therapeutics in a research report on Monday, February 5th. Finally, Oppenheimer increased their price target on shares of United Therapeutics from $375.00 to $400.00 and gave the company an "outperform" rating in a research report on Thursday, May 2nd. One analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $308.78.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of UTHR. Rise Advisors LLC acquired a new stake in United Therapeutics in the 1st quarter valued at about $32,000. GAMMA Investing LLC bought a new position in shares of United Therapeutics during the 4th quarter worth approximately $43,000. Benjamin F. Edwards & Company Inc. increased its holdings in shares of United Therapeutics by 63.6% during the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 301 shares of the biotechnology company's stock worth $69,000 after acquiring an additional 117 shares during the last quarter. C M Bidwell & Associates Ltd. bought a new position in shares of United Therapeutics in the third quarter valued at about $91,000. Finally, Janiczek Wealth Management LLC lifted its position in United Therapeutics by 21.1% during the first quarter. Janiczek Wealth Management LLC now owns 482 shares of the biotechnology company's stock worth $111,000 after acquiring an additional 84 shares during the last quarter. Institutional investors own 94.08% of the company's stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.